Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Cancer × Nivolumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 106 Melanoma 98 Neoplasms 57 Carcinoma, Renal Cell 56 Colorectal Neoplasms 38 Neoplasm Metastasis 36 Squamous Cell Carcinoma of Head and Neck 34 Stomach Neoplasms 33 Carcinoma, Hepatocellular 27 Carcinoma, Transitional Cell 24 Lung Neoplasms 21 Head and Neck Neoplasms 21 Pancreatic Neoplasms 20 Ovarian Neoplasms 20 Triple Negative Breast Neoplasms 19 Breast Neoplasms 16 Urinary Bladder Neoplasms 14 Advanced Cancer 14 Kidney Neoplasms 13 Small Cell Lung Carcinoma 12 Uterine Cervical Neoplasms 10 Recurrence 10 Lymphoma 9 Carcinoma, Merkel Cell 9 Carcinoma 9 Adenocarcinoma Of Esophagus 9 Skin Neoplasms 8 Mesothelioma 8 Hodgkin Disease 8 Esophageal Squamous Cell Carcinoma 8

Interventions

pembrolizumab 2 atezolizumab 2 trastuzumab deruxtecan 1 toripalimab 1 pertuzumab 1 durvalumab 1 cabazitaxel 1 XRP6258 1 Trastuzumab 1 S-Adenosylmethionine 1 Ramucirumab 1 Paclitaxel 1 Oxaliplatin 1 Nivolumab 1 Leucovorin 1 Irinotecan 1 Fluorouracil 1 Etoposide 1 Cetuximab 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03721679 2021-02-01

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

Oncovir, Inc.

Phase 1/2 Terminated

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡